Oncoguard® Liver

A new approach for early-stage HCC detection

Liver cancer is the fastest-growing cause of cancer-related death in the United States.1 By 2035, it is expected to be a third leading cause of cancer-related death, surpassing breast and prostate cancer.2

Outcomes for hepatocellular carcinoma (HCC), the most common type of liver cancer, are improved with early-stage detection. However, most cases of HCC are detected in late stages when curative treatments are no longer an option.3,4

The Oncoguard Liver solution includes a sophisticated, yet simple, single blood test that delivers advanced sensitivity and specificity to aid consistent and reliable HCC detection. The test is complemented by a Patient Engagement Program designed to help empower patients to proactively protect their health and follow through with routine testing. The Oncoguard Liver solution is designed with the hope of bringing better outcomes within reach for more patients at risk for HCC.

A man sitting down speaking with a nurse.

Simplifying testing to improve outcomes

Developed in collaboration with the Mayo Clinic, the Oncoguard® Liver test offers a new way to approach and detect early–stage HCC.

Advanced performance you can rely on

We believe science can simplify existing problems and deliver better outcomes for patients.

The Oncoguard Liver solution is a novel approach to accurate early-stage detection of HCC. It was built on a robust scientific platform in collaboration with experts from the Mayo Clinic. With a unique panel of DNA and protein markers carefully selected for early-stage detection, Oncoguard Liver delivers reliable results and actionable information that may put long-term survival within reach for more patients.

Innovation without inconvenience

By streamlining the process, we’ve made it more attainable for more people.

The Oncoguard Liver test is a single blood test sophisticated enough to detect early-stage HCC. With the convenience of a simple blood collection, Oncoguard Liver may streamline the surveillance process, helping patients get the vital testing they need.

Support that drives adherence

We understand that helping patients adhere to the surveillance testing that is essential to detecting HCC in its early stages is key to improving outcomes. That’s why we’re relentlessly focused on support.

The Oncoguard Liver solution includes a Patient Engagement Program that supports the care providers deliver. The flexible program offers educational materials, patient outreach, and reminders about scheduling regular testing with the aim of empowering patients to play an active role in adhering to their recommended surveillance schedule.

References

  1. Cronin KA et al (2018) Cancer.
  2. Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Network Open. 2021;4(4):e214708. doi:10.1001/jamanetworkopen.2021.4708
  3. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):e1001624. doi: 10.1371/journal.pmed.1001624.
  4. Choi DT, Kum HC, Park S, et al. Hepatocellular carcinoma screening is associated with increased survival of patients with cirrhosis. Clin Gastroenterol Hepatol. 2019;17(5):976-987.e4. doi: 10.1016/j.cgh.2018.10.031.